Literature DB >> 31179092

Secondary spontaneous pneumothorax in cancer patients.

Horiana B Grosu1, Macarena R Vial1, Mike Hernandez1, Liang Li1, Roberto F Casal1, Georgie A Eapen1, David E Ost1.   

Abstract

BACKGROUND: Malignancy-associated secondary spontaneous pneumothorax (MSSP) poses significant challenges due to limited survival. By assessing risk factors associated with a MSSP recurrence, there is potential to identify patients who could benefit from early intervention intended to prevent recurrence.
METHODS: We performed a retrospective cohort study of patients with MSSP. The primary outcome was time to MSSP recurrence. We used a competing risk model to identify risk factors associated with MSSP recurrence.
RESULTS: A total of 2,532 patients were diagnosed with pneumothorax, with 114 having MSSP but only 96 were evaluable for the time-to-recurrence analysis. Of the 96 patients, 9 (9.4%) patients experienced recurrent MSSP, and 58 (60.4%) patients died during the study's follow-up period. The estimated cumulative incidence (CI) of MSSP considering death as a competing risk was 10.1% at 15 months. The univariable model identified the following covariates as associated with MSSP recurrence: mediastinal shift (HR 12.30, 95% CI: 3.44-43.91, P<0.001), distance from lung apex to thoracic cupola (HR 1.02, 95% CI: 1.00-1.03, P=0.003), and distance between visceral and chest wall at the hilum (HR 1.02, 95% CI: 1.00-1.03, P=0.026).
CONCLUSIONS: Although the incidence of MSSP recurrence was found to be low, clinical factors such as sarcoma, the associated mediastinal shift, greater distance from lung apex to thoracic cupola, greater distance between visceral and chest wall at the hilum were found to be risk factors for MSSP recurrence.

Entities:  

Keywords:  Pneumothorax; cancer; malignancy

Year:  2019        PMID: 31179092      PMCID: PMC6531688          DOI: 10.21037/jtd.2019.03.35

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  13 in total

1.  BTS guidelines for the management of spontaneous pneumothorax.

Authors:  M Henry; T Arnold; J Harvey
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010.

Authors:  Andrew MacDuff; Anthony Arnold; John Harvey
Journal:  Thorax       Date:  2010-08       Impact factor: 9.139

3.  Spontaneous pneumothorax and pulmonary malignant disease--a syndrome sometimes associated with cavitating tumours. Report of nine new cases, four with metastases and five with primary bronchial tumours.

Authors:  F W Wright
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

4.  Resolution of experimental pneumothorax by room air.

Authors:  Ivan P Novakov; Georgi N Hadzhigeorgiev; Georgi P Safev
Journal:  Folia Med (Plovdiv)       Date:  2011 Jan-Mar

5.  Causes and outcomes of spontaneous pneumothoraces in solid tumor cancer patients: an update for the medical oncologist.

Authors:  S Ni Chan; Scott H Okuno; Aminah Jatoi
Journal:  J Thorac Oncol       Date:  2006-05       Impact factor: 15.609

6.  Civilian spontaneous pneumothorax. Treatment options and long-term results.

Authors:  J P O'Rourke; E S Yee
Journal:  Chest       Date:  1989-12       Impact factor: 9.410

Review 7.  Management of spontaneous pneumothorax.

Authors:  Michael H Baumann
Journal:  Clin Chest Med       Date:  2006-06       Impact factor: 2.878

Review 8.  Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement.

Authors:  M H Baumann; C Strange; J E Heffner; R Light; T J Kirby; J Klein; J D Luketich; E A Panacek; S A Sahn
Journal:  Chest       Date:  2001-02       Impact factor: 9.410

9.  Primary lung cancer complicated with pneumothorax.

Authors:  R S Lai; R P Perng; S C Chang
Journal:  Jpn J Clin Oncol       Date:  1992-06       Impact factor: 3.019

10.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.